Bridgeway Capital Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $630K | Buy |
443,319
+154,600
| +54% | +$220K | 0.01% | 735 |
|
|
2025
Q1 | $442K | Buy |
288,719
+7,600
| +3% | +$11.6K | 0.01% | 765 |
|
|
2024
Q4 | $697K | Buy |
281,119
+82,000
| +41% | +$203K | 0.02% | 745 |
|
|
2024
Q3 | $229K | Buy |
199,119
+48,419
| +32% | +$55.7K | 0.01% | 1034 |
|
|
2024
Q2 | $166K | Buy |
+150,700
| New | +$166K | ﹤0.01% | 1090 |
|
|
2021
Q3 | – | Sell |
-135,000
| Closed | -$2.37M | – | 1284 |
|
|
2021
Q2 | $2.37M | Sell |
135,000
-79,300
| -37% | -$1.39M | 0.04% | 558 |
|
|
2021
Q1 | $5.4M | Sell |
214,300
-25,100
| -10% | -$632K | 0.1% | 274 |
|
|
2020
Q4 | $1.55M | Sell |
239,400
-35,000
| -13% | -$226K | 0.03% | 611 |
|
|
2020
Q3 | $705K | Hold |
274,400
| – | – | 0.02% | 781 |
|
|
2020
Q2 | $445K | Buy |
+274,400
| New | +$445K | 0.01% | 893 |
|
|
2020
Q1 | – | Sell |
-87,500
| Closed | -$165K | – | 1270 |
|
|
2019
Q4 | $165K | Hold |
87,500
| – | – | ﹤0.01% | 1217 |
|
|
2019
Q3 | $95K | Hold |
87,500
| – | – | ﹤0.01% | 1248 |
|
|
2019
Q2 | $192K | Buy |
+87,500
| New | +$192K | ﹤0.01% | 1189 |
|